OOIR: Observatory of International Research

Papers

(The H4-Index of Blood is 90. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	1203
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	1176
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	669
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	531
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	487
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	366
Venous thromboembolism in cancer patients: a population-based cohort study	356
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	246
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	214
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	214
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	210
Therapeutic options in VEXAS syndrome: insights from a retrospective series	184
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	177
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	171
Antibody-induced procoagulant platelets in severe COVID-19 infection	161
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	158
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	155
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	153
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	153
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	148
Management of AL amyloidosis in 2020	147
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	143
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	141
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	141
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	138

Association of clonal hematopoiesis with chronic obstructive pulmonary disease	136
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	136
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	135
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	131
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	129
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	128
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	125
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	124
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	124
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	123
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	123
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	122
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	122
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	122
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	122
Redefining outcomes in immune TTP: an international working group consensus report	121
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells	121
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	120
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	119
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	117
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP	117
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study	115
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	114
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	114
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study	112
Real-world experience with caplacizumab in the management of acute TTP	112
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis	111
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort	111
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	110
BCL2 and MCL1 inhibitors for hematologic malignancies	110
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	110
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an	109
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL	109
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study	109
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	109
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin	108
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma	106
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells	105
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner	105
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	105
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study	105
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome	104
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results	104
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis	104
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke	102
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals	100
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma	100
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells	100
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel	100
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma	99

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination	97
Platelets and extracellular vesicles and their cross talk with cancer	97
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia	96
Cancer immunoediting and immune dysregulation in multiple myeloma	96
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	96
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group	95
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy	95
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents	95
Emicizumab for the treatment of acquired hemophilia A	95
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know	94
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML	93
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal	93
Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease	93
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults	92
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CA	91
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myel	90